Quick Answer
Galera Therapeutics, Inc. reported Research And Development Expense of $349.0 thousand for the year ending 2025.
- Galera Therapeutics, Inc. showed a decrease of -88.9% in Research And Development Expense from 2024 to 2025.
- This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $4.16 million | Q1 2019: $8.50 million | Q2 2019: $9.52 million | Q3 2019: $11.04 million | Q1 2020: $14.25 million | Q2 2020: $13.84 million | Q3 2020: $12.13 million | Q1 2021: $12.42 million | Q2 2021: $15.97 million | Q3 2021: $14.81 million | Q1 2022: $8.11 million | Q2 2022: $6.64 million | Q3 2022: $8.11 million | Q1 2023: $7.27 million | Q2 2023: $7.56 million | Q3 2023: $6.09 million | Q1 2024: $1.49 million | Q2 2024: $1.43 million | Q3 2024: $305.0 thousand | Q1 2025: $93.0 thousand | Q2 2025: $84.0 thousand | Q3 2025: $130.0 thousand.
- Over the full 8 years of available data (2018 to 2025), Galera Therapeutics, Inc.'s Research And Development Expense has declined by 98.1%.
- Historical annual values: Fiscal year 2025: $349.0 thousand | Fiscal year 2024: $3.15 million | Fiscal year 2023: $24.12 million | Fiscal year 2022: $31.01 million | Fiscal year 2021: $52.42 million | Fiscal year 2020: $54.85 million | Fiscal year 2019: $42.33 million | Fiscal year 2018: $18.66 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: